Jordan Talia1, Carole Bitar2, Yue Wang3, Michael L Whitfield3, Dinesh Khanna4. 1. University of Michigan, Department of Dermatology, Ann Arbor, MI, USA. 2. University of Michigan, Department of Pathology, Ann Arbor, MI, USA. 3. Geisel School of Medicine at Dartmouth, Department of Biomedical Data Science and Department of Molecular & Systems Biology, Lebanon, NH. 4. University of Michigan, Division of Rheumatology, Ann Arbor, MI, USA.
Abstract
INTRODUCTION: Linear morphea is an inflammatory condition that is often treated with systemic glucocorticoids and methotrexate, with mycophenolate mofetil being used as an alternative agent. However, there are few published reports on beneficial effect of abatacept for refractory disease. We present a case of a woman in her 30s who presented with linear morphea on her scalp, with a notable response following the addition of subcutaneous abatacept. METHODS: Computational analysis was performed comparing the immune cell scores of skin biopsies from 5 morphea skin biopsies from 3 unique patients and 15 healthy control skin biopsies. P < 0.05 was considered statistically significant. RESULTS: Immune cell scores demonstrated a statistically significant enrichment of activated CD4 memory T cells, M1 macrophages, monocytes, and memory B cells comparing skin biopsies of morphea vs healthy controls (p < 0.05 for all). DISCUSSION: Abatacept may be considered for recalcitrant cases of morphea. Our computational analysis supports a well-designed study to assess abatacept as first line therapy.
INTRODUCTION: Linear morphea is an inflammatory condition that is often treated with systemic glucocorticoids and methotrexate, with mycophenolate mofetil being used as an alternative agent. However, there are few published reports on beneficial effect of abatacept for refractory disease. We present a case of a woman in her 30s who presented with linear morphea on her scalp, with a notable response following the addition of subcutaneous abatacept. METHODS: Computational analysis was performed comparing the immune cell scores of skin biopsies from 5 morphea skin biopsies from 3 unique patients and 15 healthy control skin biopsies. P < 0.05 was considered statistically significant. RESULTS: Immune cell scores demonstrated a statistically significant enrichment of activated CD4 memory T cells, M1 macrophages, monocytes, and memory B cells comparing skin biopsies of morphea vs healthy controls (p < 0.05 for all). DISCUSSION: Abatacept may be considered for recalcitrant cases of morphea. Our computational analysis supports a well-designed study to assess abatacept as first line therapy.
Entities:
Keywords:
Abatacept; Linear Morphea; Localized Scleroderma; Recalcitrant; Therapeutic
Authors: Dinesh Khanna; Cathie Spino; Sindhu Johnson; Lorinda Chung; Michael L Whitfield; Christopher P Denton; Veronica Berrocal; Jennifer Franks; Bhavan Mehta; Jerry Molitor; Virginia D Steen; Robert Lafyatis; Robert W Simms; Anna Gill; Suzanne Kafaja; Tracy M Frech; Vivien Hsu; Robyn T Domsic; Janet E Pope; Jessica K Gordon; Maureen D Mayes; Elena Schiopu; Amber Young; Nora Sandorfi; Jane Park; Faye N Hant; Elana J Bernstein; Soumya Chatterjee; Flavia V Castelino; Ali Ajam; Yue Wang; Tammara Wood; Yannick Allanore; Marco Matucci-Cerinic; Oliver Distler; Ora Singer; Erica Bush; David A Fox; Daniel E Furst Journal: Arthritis Rheumatol Date: 2019-12-10 Impact factor: 10.995
Authors: M Bonelli; E Ferner; L Göschl; S Blüml; A Hladik; T Karonitsch; H P Kiener; R Byrne; B Niederreiter; C W Steiner; E Rath; M Bergmann; J S Smolen; C Scheinecker Journal: Arthritis Rheum Date: 2013-03
Authors: Jorre S Mertens; Diane Marsman; Peter C M van de Kerkhof; Esther P A H Hoppenreijs; Hanneke K A Knaapen; Timothy R D Radstake; Elke M G J de Jong; Marieke M B Seyger Journal: Acta Derm Venereol Date: 2016-05 Impact factor: 4.437
Authors: Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh Journal: Nat Methods Date: 2015-03-30 Impact factor: 28.547